Kurma Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Kurma Partners/Activity

Kurma Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Minoryx Therapeutics' NEZGLYAL (leriglitazone) received a positive CHMP opinion for treating cerebral adrenoleukodystrophy, a rare neurodegenerative disease.

Minoryx Therapeutics

Minoryx Therapeutics Kurma Partners

globenewswire.comJUL 24, 2026

JUL 24, 2026

New Fund

Announced the final closing of Biofund IV at €215 million, bringing total AUM across Kurma franchises to €1 billion.

Biofund IV

Kurma Partners

kurmapartners.comAPR 24, 2026

APR 24, 2026

New Fund

Kurma Partners closed Biofund IV at €215M, bringing total AUM across all franchises to €1 billion.

Kurma Biofund IV — €215M Final Close

Kurma Partners

kurmapartners.comAPR 2026

medcitynews.com

en.newsroom.eurazeo.com

APR 2026

Investment

Co-led Laigo Bio's oversubscribed €17 million seed financing final close to advance oncology and auto-immunity programs.

Laigo Bio

Laigo Bio Kurma Partners

kurmapartners.comMAR 23, 2026

MAR 23, 2026

Investment

Participated in Medincell's €48 million private placement.

Medincell

Medincell Kurma Partners

kurmapartners.comMAR 11, 2026

MAR 11, 2026

Exit

Portfolio company PathoQuest (NGS-based biosafety) announced acquisition by Charles River Laboratories.

PathoQuest

PathoQuest Kurma Partners

kurmapartners.comJAN 2026

kurmapartners.com

JAN 2026

3 investments· OCT 2025 – JAN 2026Show all

Investment

Participated in Alveus Therapeutics' $160M Series A for next-generation obesity and metabolic disease therapies.

Alveus Therapeutics

Alveus Therapeutics Kurma Partners

globenewswire.comJAN 2026

kurmapartners.com

JAN 2026

Investment

Led Damae Medical's €15 million Series B to accelerate 3D digital biopsy and AI-driven dermatological care.

Damae Medical

Damae Medical Kurma Partners

kurmapartners.comDEC 3, 2025

DEC 3, 2025

Investment

Co-led Adcytherix's €105M Series A — the largest ADC-focused Series A in Europe in 2025.

Adcytherix

Adcytherix Kurma Partners

adcytherix.comOCT 2025

eu-startups.com

Exit

Founding shareholder ImCheck Therapeutics acquired by Ipsen for up to €1 billion (€350M upfront).

ImCheck Therapeutics

ImCheck Therapeutics Kurma Partners

kurmapartners.comOCT 2025

kurmapartners.com

OCT 2025

3 investments· MAY 2025 – JUL 2025Show all

Investment

Kurma Growth Opportunities Fund co-led NUCLIDIUM's €84 million Series B financing for its copper-based radiopharmaceutical platform.

Nuclidium

Nuclidium Kurma Partners

kurmapartners.comJUL 10, 2025

JUL 10, 2025

Investment

Co-led Elkedonia's oversubscribed €11.25 million seed round to advance neuroplastogens for depression and neuropsychiatric disorders.

Elkedonia

Elkedonia Kurma Partners

kurmapartners.comJUN 11, 2025

JUN 11, 2025

Investment

Co-led Nuevocor's $45 million Series B financing to advance treatment for genetic dilated cardiomyopathy.

Nuevocor

Nuevocor Kurma Partners

kurmapartners.comMAY 6, 2025

MAY 6, 2025

Exit

Portfolio company Stilla Technologies (digital PCR) acquired by Bio-Rad Laboratories for $225M plus up to $50M in milestones.

Stilla Technologies

Stilla Technologies Kurma Partners

kurmapartners.comFEB 2025

FEB 2025

Page 1 of 2

kurmapartners.com

OCT 2025